Pediatric Medicines: Global Markets
The global market for pediatric medicines reached $80.7 billion in 2013 and should reach $83.6 billion in 2014. This market is expected to reach about $100.7 billion by 2019, registering a compound annual growth rate (CAGR) of 3.8% from 2014 to 2019.
- An overview of the global market for pediatric medicines.
- Analyses of global market trends, with data from 2013 and 2014, and projections of CAGRs through 2019.
- Discussion on market drivers and inhibitors, and the area of unmet clinical need.
- Information on the regulatory environment and impacts of government.
- Details pertaining to the barriers to entry for pediatric medicines.
- Market analysis for therapeutic fields including childhood cancers, CNS disorders, inflammatory diseases, metabolic diseases, respiratory conditions, vaccinations, and viral infections.
SCOPE OF REPORT
This new report on pediatric medicine will provide a brief overview on the current status of the industry and recent developments. It presents the changing environment in terms of new legislation and implementation of global pediatric plans. The report analyzes market trends and identifies key therapeutic and geographical challenges and rising opportunities in the developed and developing world. Finally, the report provides insights on how all stakeholders have an essential interest in prioritizing pediatric drug development targets and improving access to safe and effective medicines to children across the globe.
Dr. Bianca Piachaud-Moustakis has more than 10 years’ experience as a freelance writer and research analyst specializing in pharmaceutical and healthcare intelligence and has worked for a number of business intelligence providers in the U.K. She has a broad range of writing experience ranging from international academic and practitioner journals to market intelligence reports and short articles, and is author of the book “Outsourcing Research and Development in the Pharmaceutical Industry: from Conceptualization to Implementation of the Strategic Sourcing Process,” published by Palgrave Macmillan Publishers UK (2004).
Dr. Piachaud-Moustakis is also a reviewer for international peer-reviewed journals and works as a tutor on advanced-level business studies courses.
The practical pharmaceutical research experience of Dr. Cheryl L. Barton with a leading pharmaceutical company spans over 10 years; also, she has served as a Pan-European pharmaceutical analyst with a European bank. With her business, Dr. C.L. Barton Ltd., Dr. Barton provides independent, customized pharmaceutical thematic research to investment houses. Research reports combine independent scientific analysis with patient- and prescription-based models to forecast the potential sales growth of key developmental drugs and to isolate the key drivers within the pharmaceutical sector. For further information, visit www.pharmavision.co.uk.